Urispas
INDICATIONS
Urispas (flavoxate HCl) is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Urispas is not indicated for definitive treatment, but is compatible with drugs used for, the treatment of urinary tract infections.
DOSAGE AND ADMINISTRATION
Adults and children over 12 years of age: One or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced. This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.
HOW SUPPLIED
Urispas (flavoxate HCl), 100 mg, is supplied as round, white, film-coated tablets debossed with the product name URISPAS and SKF, in bottles of 100 and in Single Unit Packages of 100 (intended for institutional use only).
- 100 mg 100's: NDC 0007-5290-20
100 mg SUP 100's: NDC 0007-5290-21
Storage: Store between 15° and 30° C (59° and 86° F).
Generic Name: Flavoxate HCl
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.
Exercise for Urinary Incontinence
Like millions, Mary Lou Retton has urinary incontinence. There are no medications but pelvic muscle exercises often help. See more WebMD Videos »
